Aurobindo Pharma is currently trading at Rs 591.95, up by 2.10 points or 0.36% from its previous closing of Rs 589.85 on the BSE.
The scrip opened at Rs 594.25 and has touched a high and low of Rs 597.00 and Rs 590.20 respectively. So far 15665 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 610.40 on 05-May-2014 and a 52 week low of Rs 138.45 on 06-Aug-2013.
Last one week high and low of the scrip stood at Rs 608.50 and Rs 577.00 respectively. The current market cap of the company is Rs 17191.59 crore.
The promoters holding in the company stood at 54.61%, while Institutions and Non-Institutions held 33.59% and 11.80% respectively.
Andhra Pradesh High Court (HC) has approved the deal between Aurobindo Pharma and its wholly-owned subsidiary Curepro Parenterals. Under the Scheme of Arrangement, Aurobindo would transfer its injectables Unit IV to Curepro, and the same is to be effective from April 1, 2014.
The company will take necessary steps to make the scheme effective and intimate the exchanges accordingly.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.00 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1235.05 |
| Zydus Lifesciences | 941.20 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: